It’s not just Christmas products that are the latest victims of shrinkflation, even basic essentials such as toothpaste and ...

NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy ...

When companies hike prices on essentials like food, medicine, or medical devices, the financial rewards may be immediate—but ...

Today in the Planet Money newsletter, five recent papers that lit lightbulbs in our brains, and are maybe worth taking a look ...

Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete – Phase 3 X-NOVA2 and X-NOVA3 studies in ...

Smart BLDC fans are changing everyday comfort by using less energy, running quietly, and offering app or voice control. They represent the perfect mix of modern technology, stylish design, and smart ...

The study warns that global inequality has reached "emergency levels," putting democracy, economic stability, and climate ...

Demanding “impact” is an attempt to re-engineer the profession, questioning the entire role of academia in society. If ...

Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration ...

Cash and Cash Equivalents: As of September 30, 2025, Kymera had $978.7 million in cash, cash equivalents and investments. Kymera expects that its cash balance will provide the Company with a cash ...

Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability ...

My experiences have demonstrated that business development combined with market analysis is the most powerful pairing for ...